Cellectis
CLLS
#8362
Rank
โ‚ฌ0.25 B
Marketcap
2,54ย โ‚ฌ
Share price
1.76%
Change (1 day)
3.38%
Change (1 year)

Revenue for Cellectis (CLLS)

Revenue in 2026 (TTM): โ‚ฌ57.99 Million

According to Cellectis's latest financial reports the company's current revenue (TTM ) is โ‚ฌ59.84 Million. In 2025 the company made a revenue of โ‚ฌ62.09 Million an increase over the revenue in the year 2024 that were of โ‚ฌ39.88 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cellectis from 2015 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚ฌ57.99 M-6.6%
2025 โ‚ฌ62.09 M55.69%
2024 โ‚ฌ39.88 M5740.06%
2023 โ‚ฌ0.68 M-96.16%
2022 โ‚ฌ17.76 M-64.88%
2021 โ‚ฌ50.59 M-14.9%
2020 โ‚ฌ59.44 M340.73%
2019 โ‚ฌ13.48 M19.96%
2018 โ‚ฌ11.24 M-46.3%
2017 โ‚ฌ20.94 M-48.12%
2016 โ‚ฌ40.36 M-19.26%
2015 โ‚ฌ49.99 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Regeneron Pharmaceuticals
REGN
โ‚ฌ13.11 B 21,818.03%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
โ‚ฌ15.9 M-73.42%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
โ‚ฌ0.52 B 776.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
โ‚ฌ88.26 M 47.50%๐Ÿ‡บ๐Ÿ‡ธ USA